AG
CYTK icon

Algert Global’s Cytokinetics CYTK Stock Holding History

Algert Global’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11M Buy
129,460
+12,340
+11% +$886K 0.13% 235
2026
Q1 		$7.72M Buy
117,120
+65,810
+128% +$4.18M 0.12% 290
2025
Q4 		$3.26M Sell
51,310
-1,150
-2% -$71.5K 0.05% 579
2025
Q3 		$2.88M Sell
52,460
-7,930
-13% -$327K 0.05% 573
2025
Q2 		$2M Sell
60,390
-55,930
-48% -$1.95M 0.04% 636
2025
Q1 		$4.67M Buy
116,320
+57,640
+98% +$2.65M 0.12% 301
2024
Q4 		$2.76M Buy
58,680
+10,010
+21% +$520K 0.07% 500
2024
Q3 		$2.57M Sell
48,670
-22,738
-32% -$1.27M 0.07% 477
2024
Q2 		$3.87M Buy
71,408
+27,738
+64% +$1.67M 0.13% 250
2024
Q1 		$3.06M Sell
43,670
-150
-0.3% -$11.6K 0.12% 288
2023
Q4 		$3.66M Buy
43,820
+28,370
+184% +$1.03M 0.15% 224
2023
Q3 		$455K Buy
+15,450
New +$515K 0.02% 773
2023
Q1 		– Sell
-39,143
Closed -$1.79M – 1166
2022
Q4 		$1.79M Hold
39,143
– – 0.1% 329
2022
Q3 		$1.9M Buy
39,143
+5,917
+18% +$285K 0.11% 286
2022
Q2 		$1.3M Buy
33,226
+358
+1% +$14.4K 0.1% 365
2022
Q1 		$1.21M Buy
32,868
+27,948
+568% +$993K 0.08% 441
2021
Q4 		$224K Buy
+4,920
New +$190K 0.03% 816
2021
Q1 		– Sell
-36,684
Closed -$762K – 457
2020
Q4 		$762K Buy
+36,684
New +$670K 0.22% 164
2019
Q4 		– Sell
-14,388
Closed -$164K – 395
2019
Q3 		$164K Buy
+14,388
New +$181K 0.06% 293
2015
Q4 		– Sell
-73,181
Closed -$490K – 334
2015
Q3 		$490K Hold
73,181
– – 0.27% 145
2015
Q2 		$492K Hold
73,181
– – 0.27% 136
2015
Q1 		$496K Sell
73,181
-4,669
-6% -$34.9K 0.28% 149
2014
Q4 		$624K Buy
77,850
+48,910
+169% +$210K 0.37% 107
2014
Q3 		$102K Buy
28,940
+9,190
+47% +$38.6K 0.08% 264
2014
Q2 		$94K Buy
+19,750
New +$121K 0.06% 277

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Algert Global's CYTK Position: Q2 2026 in Review

Algert Global increased its Cytokinetics (CYTK) stake by 11% in Q2 2026, buying an estimated $886K and bringing the position to 129,460 shares worth $11M. The position accounts for 0.13% of the portfolio, ranked #235.

Algert Global first reported a position in CYTK in Q2 2014 and has held it in 25 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Algert Global held 129,460 shares of Cytokinetics worth $11M as of Q2 2026.
  • Algert Global bought 12,340 Cytokinetics shares in Q2 2026, an estimated $886K.
  • Cytokinetics made up 0.13% of Algert Global's portfolio in Q2 2026, its #235 holding.
  • Algert Global first reported a position in Cytokinetics in Q2 2014 and has held it in 25 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.